Barrons
09 Jul 2026, 11:38 UTC · 2h ago
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Barrons
09 Jul 2026, 11:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
AstraZeneca and Ionis Pharmaceuticals' gene silencing drug, Wainua, failed its late-stage clinical trial. — Late-stage failures eliminate the immediate path to commercialization and typically lead to significant valuation write-downs for the involved drug candidates.
-0.80Which stocks this story touches
The company experienced a late-stage trial failure for its drug Wainua.
The company experienced a late-stage trial failure for its drug Wainua.
Continue reading
6 related stories
Top 2 movers · tap to explore
[mutual] AstraZeneca and Ionis Pharmaceuticals are partners in the development of the gene silencing drug Wainua.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
6h ago
